Abstract
Background Electronic frailty indices can be useful surrogate measures of frailty. We assessed the role of machine learning to develop an electronic frailty index, incorporating demographics, baseline comorbidities, healthcare utilization characteristics, electrocardiographic measurements, and laboratory examinations, and used this to predict all-cause mortality in patients undergoing transaortic valvular replacement (TAVR).
Methods This was a multi-centre retrospective observational study of patients undergoing for TAVR. Significant univariate and multivariate predictors of all-cause mortality were identified using Cox regression. Importance ranking of variables was obtained with a gradient boosting survival tree (GBST) model, a supervised sequential ensemble learning algorithm, and used to build the frailty models. Comparisons were made between multivariate Cox, GBST and random survival forest models.
Results A total of 450 patients (49% females; median age at procedure 82.3 (interquartile range, IQR 79.0-86.0)) were included, of which 22 died during follow-up. A machine learning survival analysis model found that the most important predictors of mortality were APTT, followed by INR, severity of tricuspid regurgitation, cumulative hospital stays, cumulative number of readmissions, creatinine, urate, ALP, and QTc/QT intervals. GBST significantly outperformed random survival forests and multivariate Cox regression (precision: 0.91, recall: 0.89, AUC: 0.93, C-index: 0.96, and KS-index: 0.50) for mortality prediction.
Conclusions An electronic frailty index incorporating multi-domain data can efficiently predict all-cause mortality in patients undergoing TAVR. A machine learning survival learning model significantly improves the risk prediction performance of the frailty models.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by The Joint Chinese University of Hong Kong - New Territories East Cluster Clinical Research Ethics Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The dataset has already been deposited in a repository and is accessible via: https://zenodo.org/record/4387098
